Tecan and the Monash Antibody Technologies Facility join forces to produce monoclonal antibody production facility
New state-of-the-art monoclonal antibody production system capable of producing thousands of novel antibodies every year for researchers around the world
In the research world, the use of monoclonal antibodies has proven crucial to the understanding of a myriad of physiological processes, and has led to new approaches in the treatment of diseases with great unmet clinical need. In the medical world, they are currently used as diagnostic agents to detect cancers or infectious diseases; as vaccines to boost the body's immune response; and as therapeutics, to target cancerous cells or to decrease the body's own immune response in diseases such as rheumatoid arthritis and multiple sclerosis.
The MATF is one of the only high throughput production facilities in the world offering custom-made, high-affinity monoclonal antibodies. The new system will increase the production capacity at MATF from original estimates of 500 panels of novel antibodies a year to potentially 5,000, helping to alleviate the bottleneck of antibody supply experienced by many researchers working on protein function and physiological processes.
The new system, partially funded by the Victorian State Government and Monash University, National Collaborative Research Infrastructure Strategy and the Australian Stem Cell Centre, is the first major step towards an extensive assay development program planned for 2008, which will further strengthen Monash University's rising profile as a centre of excellence in the international medical research community.
Tecan's team of experienced application specialists and engineers will build the new system at the company's headquarters in Männedorf, Switzerland, ready for installation at the MATF in April 2008.
Most read news
Other news from the department manufacturing
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous